详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Dermatology and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China. [2]Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network West China Hospital, Sichuan University, Chengdu 610041, China. [3]NHC Key Lab of Transplant Engineering and Immunology, Organ Transplant Center, West China Hospital, Sichuan University, Chengdu, Chengdu 610041, China. [4]Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa. [5]Sichuan Provincial Engineering Laboratory of Pathology in Clinical Application, West China Hospital, Sichuan University.

出处：

DOI：

摘要：

Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer treatment modality based on a target-specific photosensitizer conjugate (TSPC) composed of an NIR phthalocyanine photosensitizer and an antigen-specific recognition system. NIR-PIT has predominantly been used for targeted therapy of tumors via local irradiation with NIR light, following binding of TSPC to antigen-expressing cells. Physical stress-induced membrane damage is thought to be a major mechanism underlying NIR-PIT-triggered photokilling. Notably, NIR-PIT can rapidly induce immunogenic cell death and activate the adaptive immune response, thereby enabling its combination with immune checkpoint inhibitors. Furthermore, NIR-PIT-triggered "super-enhanced permeability and retention" effects can enhance drug delivery into tumors. Supported by its potential efficacy and safety, NIR-PIT is a rapidly developing therapeutic option for various cancers. Hence, this review seeks to provide an update on the (i) broad range of target molecules suitable for NIR-PIT, (ii) various types of receptor-selective ligands for designing the TSPC "magic bullet," (iii) NIR light parameters, and (iv) strategies for enhancing the efficacy of NIR-PIT. Moreover, we review the potential application of NIR-PIT, including the specific design and efficacy in 19 different cancer types, and its clinical studies. Finally, we summarize possible NIR-PIT applications in noncancerous conditions, including infection, pain, itching, metabolic disease, autoimmune disease, and tissue engineering.© The author(s).

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 1 区

医学

小类 | 1 区医学：研究与实验

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区医学：研究与实验

第一作者：

第一作者机构： [1]Department of Dermatology and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China. [2]Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network West China Hospital, Sichuan University, Chengdu 610041, China. [3]NHC Key Lab of Transplant Engineering and Immunology, Organ Transplant Center, West China Hospital, Sichuan University, Chengdu, Chengdu 610041, China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Dermatology and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China. [2]Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network West China Hospital, Sichuan University, Chengdu 610041, China. [3]NHC Key Lab of Transplant Engineering and Immunology, Organ Transplant Center, West China Hospital, Sichuan University, Chengdu, Chengdu 610041, China. [5]Sichuan Provincial Engineering Laboratory of Pathology in Clinical Application, West China Hospital, Sichuan University. [*1]NHC Key Lab of Transplant Engineering and Immunology, West China Hospital, Sichuan University, No. 1 KeYuan 4th Road, Chengdu, 610041, China [*2]Department of Dermatology, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, 610041, China

推荐引用方式(GB/T 7714)：

APA：

MLA：